EZH2基因低甲基化在胶质瘤患者病情和预后评估中的价值  

Value of enhancer of EZH2 gene hypomethylation in evaluation of glioma condition and prognosis

作　　者：李巍 邢永国 李玉斌 门树乐 张鹏飞 焦德让 Li Wei;Xing Yongguo;Li Yubin;Men Shule;Zhang Pengfei;Jiao Derang(Department of Neurosurgery,Beichen District Hospital of Traditional Chinese Medicine,Tianjin 300400,China)

机构地区：[1]天津市北辰区中医医院神经外科,天津300400

出　　处：《国际生物医学工程杂志》2023年第6期558-561,共4页International Journal of Biomedical Engineering

摘　　要：目的分析zeste基因增强子同源物2(EZH2)基因在胶质瘤患者病情及预后评估中的价值。方法选取2017年1月至2018年12月天津市北辰区中医医院诊治的90例脑胶质瘤患者为胶质瘤组,另选择同期45例颅脑良性疾病患者为对照组。采用甲基特异性PCR检测胶质瘤患者(肿瘤组织、癌旁正常组织)、对照组颅脑组织及胶质瘤细胞SHG-44、U251、U87和CRT细胞中EZH2基因甲基化状态;分析EZH2基因未甲基化与胶质瘤患者临床病理因素的关系;Kaplan-Meier生存分析胶质瘤患者肿瘤组织中EZH2基因未甲基化和甲基化的生存差异。结果胶质瘤组患者肿瘤组织EZH2基因未甲基化率(68.9%)高于胶质瘤组癌旁正常组织(5.6%)和对照组(4.4%),差异均有统计学意义(P<0.05)。SHG-44、U251、U87和CRT细胞中EZH2基因处于未甲基化状态。胶质瘤组患者肿瘤组织EZH2基因未甲基化率在颅内高压、肿瘤最大径、肿瘤数量和世界卫生组织(WHO)分级方面的差异均有统计学意义(均P<0.05),有颅内高压、肿瘤最大径≥5 cm、多发及Ⅲ+Ⅳ级胶质瘤患者EZH2基因未甲基化率显著高于无颅内高压、肿瘤最大径<5 cm、单发及Ⅰ+Ⅱ级胶质瘤患者,差异均有统计学意义(均P<0.05)。EZH2基因未甲基化患者中位生存期为(13.45±3.15)个月,EZH2基因甲基化患者中位生存期为(19.45±3.56)个月,显著高于未甲基化患者(Logrank=30.084,P<0.05)。结论EZH2基因在胶质瘤肿瘤组织中呈低甲基化状态,可作为胶质瘤病情及预后评估的分子标志物。ObjectiveTo detect the enhancer of zeste 2 polycomb repressive complex 2 subunit(EZH2)in glioma patients and analyze its value in disease and prognosis evaluation.MethodsPatients with glioma(glioma group,90 cases)and patients with benign brain diseases(control group,45 cases)in Beichen District Hospital of Traditional Chinese Medicine from January 2017 to December 2018 were selected as the research subjects.Methyl-specific PCR was employed to detect the methylation status of the EZH2 gene of the patients in the glioma group(tumor tissue,adjacent normal tissue),the control group(brain tissue),and in glioma cell lines(SHG-44,U251,U87,and CRT).The relationship between EZH2 gene unmethylation and clinicopathological factors was analyzed.The survival difference between the unmethylated and methylated EZH2 gene in tumor tissue of glioma patients was analyzed by Kaplan-Meier survival analysis.ResultsThe unmethylated rate of the EZH2 gene in the tumor tissue of the glioma group(68.9%)is significantly higher than that of the control group(5.6%)and in the normal tissue adjacent to the tumor(4.4%),and the differences are statistically significant(all P<0.05).The EZH2 gene of glioma cell lines such as SHG-44,U251,U87,and CRT is unmethylated.There are significant differences in the unmethylated rate of the EZH2 gene in the tumor tissue of the glioma group in terms of intracranial hypertension,maximum tumor diameter,tumor number,and WHO grade(all P<0.05).The unmethylated rate of the EZH2 gene in patients with intracranial hypertension,tumor maximum diameter≥5 cm,multiple and gradeⅢ+Ⅳgliomas is significantly higher than that without intracranial hypertension,tumor maximum diameter<5 cm,single and gradeⅠ+Ⅱgliomas,and the difference is statistically significant(all P<0.05).The median survival time of EZH2 unmethylated patients is(13.45±3.15)months,and the median survival time of EZH2 methylated patients is(19.45±3.56)months.The median survival time of EZH2 methylated patients is significantly higher than that of unmet

关 键 词：胶质瘤 zeste基因增强子同源物2 甲基化 病情 预后 

分 类 号：R739.4[医药卫生—肿瘤]